查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1775476

組織診斷市場：2025-2030 年預測

Tissue Diagnostics Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

組織診斷市場預計將從 2025 年的 69.29 億美元成長到 2030 年的 94.09 億美元，複合年成長率為 6.31%。

慢性病盛行率上升

慢性疾病（尤其是癌症）的日益普及是組織診斷市場的主要驅動力。世界衛生組織 (WHO) 報告稱，到 2024 年，慢性疾病將佔全球死亡人數的 74%，其中癌症是首要原因。組織診斷涵蓋免疫組織化學 (IHC)、原位雜合反應(ISH) 和數位病理學等技術，對於精準診斷和個人化治療方案至關重要。這些工具能夠對組織異常進行詳細分析，並支援乳癌和肺癌等疾病的個人化治療，從而推動對先進診斷解決方案的需求。

老年人口不斷增加

全球人口老化是市場成長的主要驅動力。到2024年，60歲及以上人口比例將持續上升，尤其是在已開發地區，這將導致癌症和其他慢性疾病的易感性增加。這些人口結構變化推動了對組織診斷的需求，以促進早期發現和治療，尤其是在腫瘤學領域，準確的診斷對於改善患者預後至關重要。

積極的政府舉措

世界各國政府正在透過支持性政策和資金來推動組織診斷的發展。 2023年，歐盟津貼用於推動精準醫療，並專注於基於組織的癌症篩檢診斷。同樣，美國國家癌症研究所也在2024年支持先進診斷技術的研究，以促進市場應用和創新。

診斷創新

技術進步正在改變組織診斷。 2023年，羅氏的 DISCOVERY ULTRA 系統因其自動化 IHC 和 ISH 檢測能力而廣受歡迎，該系統可在 30 個獨立的載玻片抽屜上同時進行手動和自動化實驗。該系統支援 FISH 和多重蛋白質 IHC/ISH 等複雜檢測，從而提高了診斷準確性。此類創新簡化了醫院和實驗室的工作流程，以滿足對快速、準確診斷日益成長的需求。

醫院採用率高

由於基於組織的診斷解決方案比傳統方法更快、更準確，醫院正擴大採用此類解決方案。慢性病（尤其是癌症）負擔的不斷加重，推動了2024年醫院對組織診斷的需求。這些解決方案能夠加快診斷速度，這對於需要即時干涉的疾病（例如腫瘤和心血管疾病）至關重要，從而進一步推動市場成長。

市場限制

高成本

先進組織診斷設備和試劑的高成本限制了其應用，尤其是在開發中地區。截至2024年，儘管數位病理平台等自動化系統效率高，但其成本仍是小型醫療機構的一大障礙。

監理複雜性

不同地區不同的法律規範帶來了挑戰：2023 年，歐盟嚴格的核准流程減緩了新診斷工具的推出，增加了製造商的合規成本並減緩了市場擴張。

技術專長要求

有效使用先進的組織診斷技術需要專門的培訓，而這在開發中地區往往非常有限。截至2024年，這一差距將繼續阻礙亞太地區和非洲地區醫療基礎設施仍低度開發地區的廣泛應用。

市場區隔分析

依技術

免疫組織化學 (IHC) 因其在癌症診斷中的廣泛應用而佔據主導地位。 IHC 能夠精準偵測分子標記，預計到 2024 年將佔市場收益的 40% 以上。數位病理學是成長最快的領域，這得益於人工智慧的整合，以增強影像分析能力。

按用途

癌症診斷正處於領先地位，其中組織診斷對於識別腫瘤類型和指導標靶治療至關重要。其他應用，例如感染疾病診斷和自體免疫疾病診斷，由於疾病盛行率的上升而正在穩步成長。

按最終用戶

醫院佔比最大，越來越多醫院採用組織診斷技術進行快速且準確的檢測。 2024年外包趨勢將推動診斷實驗室規模擴張。

地理洞察力

以美國為首的北美將主導市場，到2024年將佔38%的佔有率。歐洲則以德國和英國為首，這兩個國家正專注於早期診斷和篩檢計畫。亞太地區是一個快速成長的地區，中國和印度將在2023年大力投資診斷基礎設施，以應對不斷上升的慢性病發病率。

競爭格局

羅氏、雅培、安捷倫科技、BD 和康德樂等主要企業正在推動技術創新。 2023 年，羅氏推出了自動化 IHC 系統，增強了其產品組合；安捷倫則於 2024 年推出了整合 AI 的數位病理解決方案。這些公司利用研發和策略夥伴關係關係來維持市場領先地位。

本報告的主要優點

  • 深刻分析：獲得深入的市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場，涵蓋主要地區和新興地區。
  • 競爭格局：了解主要企業採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力進行策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾範圍廣：對於新興企業、研究機構、顧問、中小企業和大型企業來說都是有益且具成本效益的。

它有什麼用途？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、監管影響、新產品開發、競爭情報

調查範圍

  • 實際數據為2022年至2024年，預測數據為2025年至2030年
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第1章執行摘要

第2章市場概述

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機會
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

第 5 章：組織診斷市場（按產品）

  • 介紹
  • 耗材
    • 抗體
    • 套件
    • 探測
    • 試劑
  • 裝置
    • 幻燈片掃描儀
    • 玻片染色系統
    • 組織微陣列
    • 組織處理系統
    • 其他

第6章：組織診斷市場（依技術）

  • 介紹
  • 數位病理學
  • 免疫組織化學（IHC）
  • 原位雜合技術（ISH）
  • 其他

第7章：組織診斷市場（按應用）

  • 介紹
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 胃癌
  • 肺癌
  • 其他

第 8 章：組織診斷市場（依最終使用者）

  • 介紹
  • 合約研究組織（CRO）
  • 醫院
  • 診斷中心
  • 其他

第 9 章：按地區分類的組織診斷市場

  • 介紹
  • 北美洲
    • 按產品
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按產品
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 按產品
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家
      • 德國
      • 法國
      • 英國
      • 西班牙
      • 其他
  • 中東和非洲
    • 按產品
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 按產品
    • 依技術
    • 按用途
    • 按最終用戶
    • 按國家
      • 中國
      • 印度
      • 日本
      • 韓國
      • 印尼
      • 其他

第10章競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton Dickinson
  • BioGenex
  • Cardinal Health
  • Danaher
  • F. Hoffmann-La Roche Ltd
  • Medtronic
  • Merck KgaA
  • Thermo Fisher Scientific Inc.

第12章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061610034

The tissue diagnostics market is expected to grow from USD 6.929 billion in 2025 to USD 9.409 billion in 2030, at a CAGR of 6.31%.

Rising Prevalence of Chronic Diseases

The increasing incidence of chronic diseases, particularly cancer, is a primary driver of the tissue diagnostics market. In 2024, the World Health Organization reported that chronic diseases accounted for 74% of global deaths, with cancer being a leading cause. Tissue diagnostics, encompassing techniques like immunohistochemistry (IHC), in situ hybridization (ISH), and digital pathology, are critical for accurate diagnosis and personalized treatment planning. These tools enable detailed analysis of tissue abnormalities, supporting tailored therapies for conditions like breast and lung cancer, driving demand for advanced diagnostic solutions.

Growing Geriatric Population

The global aging population is significantly boosting market growth. In 2024, the proportion of individuals aged 60 and older continued to rise, particularly in developed regions, increasing susceptibility to cancers and other chronic conditions. This demographic shift has heightened the need for tissue diagnostics to facilitate early detection and treatment, especially in oncology, where precise diagnostics are essential for improving patient outcomes.

Favorable Government Initiatives

Governments worldwide are promoting tissue diagnostics through supportive policies and funding. In 2023, the European Union allocated grants to advance precision medicine, emphasizing tissue-based diagnostics for cancer screening. Similarly, U.S. initiatives under the National Cancer Institute in 2024 supported research into advanced diagnostic technologies, fostering adoption and innovation in the market.

Diagnostic Innovations

Technological advancements are transforming tissue diagnostics. In 2023, Roche's DISCOVERY ULTRA system gained traction for its ability to automate IHC and ISH assays, enabling simultaneous manual and automated experiments with 30 independent slide drawers. This system supports complex assays like FISH and multiplex protein IHC/ISH, enhancing diagnostic accuracy. Such innovations streamline workflows in hospitals and laboratories, meeting the growing demand for rapid, precise diagnostics.

High Hospital Adoption

Hospitals are increasingly adopting tissue-based diagnostic solutions due to their speed and accuracy compared to conventional methods. In 2024, the rising burden of chronic diseases, particularly cancer, drove hospital demand for tissue diagnostics. These solutions enable faster diagnosis, critical for conditions requiring immediate intervention, such as oncology and cardiovascular diseases, further propelling market growth.

Market Restraints

High Costs

The high cost of advanced tissue diagnostic instruments and reagents limits adoption, particularly in developing regions. In 2024, the cost of automated systems like digital pathology platforms remained a barrier for smaller healthcare facilities, despite their efficiency.

Regulatory Complexity

Diverse regulatory frameworks across regions pose challenges. In 2023, stringent approval processes in the EU delayed the rollout of new diagnostic tools, increasing compliance costs for manufacturers and slowing market expansion.

Technical Expertise Requirements

The effective use of advanced tissue diagnostics requires specialized training, which is often limited in developing regions. In 2024, this gap hindered adoption in parts of Asia-Pacific and Africa, where healthcare infrastructure is still evolving.

Market Segmentation Analysis

By Technology

Immunohistochemistry (IHC) dominates due to its widespread use in cancer diagnostics. In 2024, IHC accounted for over 40% of market revenue, driven by its precision in detecting molecular markers. Digital pathology is the fastest-growing segment, fueled by AI integration for enhanced image analysis.

By Application

Cancer diagnosis leads, with tissue diagnostics critical for identifying tumor types and guiding targeted therapies. Other applications, like infectious and autoimmune disease diagnostics, are growing steadily due to rising disease prevalence.

By End-User

Hospitals hold the largest share, driven by high adoption of tissue diagnostics for rapid and accurate testing. Diagnostic laboratories are expanding, supported by outsourcing trends in 2024.

Geographical Insights

North America, led by the U.S., dominates the market, holding a 38% share in 2024, driven by advanced healthcare infrastructure and a high cancer burden. Europe follows, with Germany and the UK leading due to strong focus on early diagnosis and screening programs. Asia-Pacific is the fastest-growing region, with China and India investing heavily in diagnostic infrastructure in 2023 to address rising chronic disease rates.

Competitive Landscape

Key players, including Roche, Abbott Laboratories, Agilent Technologies, BD, and Cardinal Health, drive innovation. In 2023, Roche enhanced its portfolio with automated IHC systems, while Agilent introduced AI-integrated digital pathology solutions in 2024. These companies leverage R&D and strategic partnerships to maintain market leadership.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Market Segmentation:

By Product

  • Consumables
  • Antibodies
  • Kits
  • Probes
  • Reagents
  • Instruments
  • Slide Scanners
  • Slide Staining Systems
  • Tissue Microarrays
  • Tissue Processing Systems
  • Others

By Technology

  • Digital Pathology
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Others

By Application

  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Gastric cancer
  • Lung cancer
  • Others

By End-Users

  • Contract Research Organizations (CROs)
  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • South Korea
  • India
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. TISSUE DIAGNOSTICS MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Consumables
    • 5.2.1. Antibodies
    • 5.2.2. Kits
    • 5.2.3. Probes
    • 5.2.4. Reagents
  • 5.3. Instruments
    • 5.3.1. Slide Scanners
    • 5.3.2. Slide Staining System
    • 5.3.3. Tissue Microarrays
    • 5.3.4. Tissue Processing System
    • 5.3.5. Others

6. TISSUE DIAGNOSTICS MARKET BY TECHNOLOGY

  • 6.1. Introduction
  • 6.2. Digital Pathology
  • 6.3. Immunohistochemistry (IHC)
  • 6.4. In Situ Hybridization (ISH)
  • 6.5. Others

7. TISSUE DIAGNOSTICS MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Cervical Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Gastric Cancer
  • 7.6. Lung Cancer
  • 7.7. Others

8. TISSUE DIAGNOSTICS MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Contract Research Organization (CRO)
  • 8.3. Hospitals
  • 8.4. Diagnostics Centers
  • 8.5. Others

9. TISSUE DIAGNOSTICS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Technology
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Technology
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
      • 9.4.5.2. France
      • 9.4.5.3. United Kingdom
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Technology
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Technology
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. India
      • 9.6.5.3. Japan
      • 9.6.5.4. South Korea
      • 9.6.5.5. Indonesia
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Abbott Laboratories
  • 11.2. Agilent Technologies, Inc.
  • 11.3. Becton Dickinson
  • 11.4. BioGenex
  • 11.5. Cardinal Health
  • 11.6. Danaher
  • 11.7. F. Hoffmann-La Roche Ltd
  • 11.8. Medtronic
  • 11.9. Merck KgaA
  • 11.10. Thermo Fisher Scientific Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key benefits for the stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations